SOUTH
SAN FRANCISCO, Calif., April 10,
2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
("Rigel") (Nasdaq: RIGL) today announced that it has granted awards
pursuant to Rigel's Inducement Plan, approved by the Compensation
Committee of Rigel's Board of Directors and granted as an
inducement material to employees' entering into employment with
Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Specifically, Rigel granted 407,325 stock options to nine
non-executive employees on April 4,
2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's
Chief Medical Officer, on March 27,
2024, vesting over four years with a one-year cliff.
Additionally, on March 27, 2024, Ms.
Rojkjaer was granted 187,500 stock options to vest upon achievement
of certain future performance conditions, subject to her continuous
service to the Company on such vesting date.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel
Rigel Pharmaceuticals, Inc.
(Nasdaq: RIGL) is a biotechnology company
dedicated to discovering, developing and providing novel therapies
that significantly improve the lives of patients with hematologic
disorders and cancer. Founded in 1996, Rigel is based
in South San Francisco,
California. For more information on Rigel, the
Company's marketed products and pipeline of potential products,
visit www.rigel.com.
Investors & Media Contacts
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302113555.html
SOURCE Rigel Pharmaceuticals, Inc.